Naiditch H, Betts M, Larman H, Levi M, Rosenberg A
Front Immunol. 2025; 15:1376654.
PMID: 40012912
PMC: 11861071.
DOI: 10.3389/fimmu.2024.1376654.
Agudelo C, Kateete D, Nasinghe E, Kamulegeya R, Lubega C, Mbabazi M
Gut Pathog. 2025; 17(1):9.
PMID: 39905557
PMC: 11796075.
DOI: 10.1186/s13099-025-00678-4.
Gallo A, Sammartino J, Vazzana R, Giambruno R, Carcione C, Cuscino N
J Transl Med. 2025; 23(1):151.
PMID: 39905461
PMC: 11796281.
DOI: 10.1186/s12967-025-06158-2.
Stavropoulos A, Filippou D
Croat Med J. 2025; 65(6):510-517.
PMID: 39812100
PMC: 11748445.
Wang C, Zhou X, Wang M, Chen X
Infect Microbes Dis. 2024; 3(1):14-21.
PMID: 38630064
PMC: 8011344.
DOI: 10.1097/IM9.0000000000000045.
COVID-19 and the brain: understanding the pathogenesis and consequences of neurological damage.
Maliha S, Fatemi R, Araf Y
Mol Biol Rep. 2024; 51(1):318.
PMID: 38386201
DOI: 10.1007/s11033-024-09279-x.
A Review on Role of Inflammation in Coronavirus Disease.
Lotfi A, Hajian P, Abbasi L, Gargari M, Fard N, Naderi D
Endocr Metab Immune Disord Drug Targets. 2024; 24(13):1488-1505.
PMID: 38303532
DOI: 10.2174/0118715303265274231204075802.
Leveraging immunoliposomes as nanocarriers against SARS-CoV-2 and its emerging variants.
Mohammad Faizal N, Ramli N, Mat Rani N, Shaibie N, Aarti , Poonsawas P
Asian J Pharm Sci. 2023; 18(6):100855.
PMID: 38125653
PMC: 10730353.
DOI: 10.1016/j.ajps.2023.100855.
Substances of abuse and their effect on SAR-CoV-2 pathogenesis.
Antwi I, Watkins D, Pedawi A, Ghrayeb A, Van de Vuurst C, Cory T
NeuroImmune Pharm Ther. 2023; 2(3):301-316.
PMID: 38013836
PMC: 10474379.
DOI: 10.1515/nipt-2023-0004.
Lipid Mediators and Cytokines/Chemokines Display Differential Profiles in Severe versus Mild/Moderate COVID-19 Patients.
Ravindran R, OConnor E, Gupta A, Luciw P, Khan A, Dorreh N
Int J Mol Sci. 2023; 24(17).
PMID: 37685858
PMC: 10488250.
DOI: 10.3390/ijms241713054.
Immune landscape and redox imbalance during neurological disorders in COVID-19.
Thakur A, Sharma V, Averbek S, Liang L, Pandya N, Kumar G
Cell Death Dis. 2023; 14(9):593.
PMID: 37673862
PMC: 10482955.
DOI: 10.1038/s41419-023-06102-6.
Steroid in the Treatment of Outpatient COVID-19: A Multicenter Randomized Controlled Trial.
Amra B, Vaezi A, Soltaninejad F, Salahi M, Salmasi M, Javanmard S
Adv Biomed Res. 2023; 12:122.
PMID: 37434926
PMC: 10331530.
DOI: 10.4103/abr.abr_72_22.
Macrophage phagocytosis of SARS-CoV-2-infected cells mediates potent plasmacytoid dendritic cell activation.
Garcia-Nicolas O, Godel A, Zimmer G, Summerfield A
Cell Mol Immunol. 2023; 20(7):835-849.
PMID: 37253946
PMC: 10227409.
DOI: 10.1038/s41423-023-01039-4.
Intraocular inflammation following COVID-19 vaccination: the clinical presentations.
Li S, Ho M, Mak A, Lai F, Brelen M, Chong K
Int Ophthalmol. 2023; 43(8):2971-2981.
PMID: 37000311
PMC: 10064965.
DOI: 10.1007/s10792-023-02684-4.
Therapeutic Effects of Cannabinoids and Their Applications in COVID-19 Treatment.
Perez R, Glaser T, Villegas C, Burgos V, Ulrich H, Paz C
Life (Basel). 2022; 12(12).
PMID: 36556483
PMC: 9784976.
DOI: 10.3390/life12122117.
SARS-CoV-2 infection of phagocytic immune cells and COVID-19 pathology: Antibody-dependent as well as independent cell entry.
Matveeva O, Nechipurenko Y, Lagutkin D, Yegorov Y, Kzhyshkowska J
Front Immunol. 2022; 13:1050478.
PMID: 36532011
PMC: 9751203.
DOI: 10.3389/fimmu.2022.1050478.
IL-33 and the Cytokine Storm in COVID-19: From a Potential Immunological Relationship towards Precision Medicine.
Furci F, Murdaca G, Allegra A, Gammeri L, Senna G, Gangemi S
Int J Mol Sci. 2022; 23(23).
PMID: 36498859
PMC: 9740753.
DOI: 10.3390/ijms232314532.
New‑onset neuropsychiatric sequelae and 'long‑COVID' syndrome (Review).
Efstathiou V, Stefanou M, Demetriou M, Siafakas N, Katsantoni E, Makris M
Exp Ther Med. 2022; 24(5):705.
PMID: 36324612
PMC: 9622976.
DOI: 10.3892/etm.2022.11641.
Analysis of post COVID-19 condition and its overlap with myalgic encephalomyelitis/chronic fatigue syndrome.
Sukocheva O, Maksoud R, Beeraka N, Madhunapantula S, Sinelnikov M, Nikolenko V
J Adv Res. 2022; 40:179-196.
PMID: 36100326
PMC: 8619886.
DOI: 10.1016/j.jare.2021.11.013.
K18- and CAG-hACE2 Transgenic Mouse Models and SARS-CoV-2: Implications for Neurodegeneration Research.
Dedoni S, Avdoshina V, Camoglio C, Siddi C, Fratta W, Scherma M
Molecules. 2022; 27(13).
PMID: 35807384
PMC: 9268291.
DOI: 10.3390/molecules27134142.
